



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** October 30, 2009

**To:** Primary Clinical Research Associates

**From:** Sara Braun  
Research Protocol Specialist III

**Re:** N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

The “Event Monitoring Form” has been revised as follows.

<b>Form Title</b>	<b>Brief Description of Edit</b>
Event Monitoring Form	<ul style="list-style-type: none"><li>Added section to collect Notice of Subsequent Surgery or Biopsy</li></ul>

If you have any questions, please feel free to contact me.

Enclosure